In patients with type 2 severe asthma, characterized by eosinophilic or phenoendotypes, monoclonal antibodies have been developed to block key cytokines such as IL-5, IL-4, IL-13, and immunoglobulin E (IgE) [4]. This evidence concerns the gene IL5 and asthma.